Taizhou EOC Pharma Co., Ltd.
7 clinical trials · Sponsor
◉ Watch Taizhou EOC Pharma Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy (NCT05322720) | Taizhou EOC Pharma Co., Ltd. | 2022-04-01 |
| Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer (NCT03817411) | Taizhou EOC Pharma Co., Ltd. | 2019-01-25 |
| Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer (NCT03600090) | Taizhou EOC Pharma Co., Ltd. | 2018-10-16 |
| Study of EOC317 in Chinese Patients With Advanced Solid Tumors (NCT03583125) | Taizhou EOC Pharma Co., Ltd. | 2018-05-29 |
| Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer (NCT03538171) | Taizhou EOC Pharma Co., Ltd. | 2018-05-15 |
Track Taizhou EOC Pharma Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.